Peer Review History

Original SubmissionApril 3, 2025
Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

Decision Letter - Ken Iseri, Editor

Dear Dr. Yahyaoui,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:  Please respond reviewer's concerns.

==============================

Please submit your revised manuscript by Jul 31 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Ken Iseri

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

Additional Editor Comments:

Please respond reviewer's concerns.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: No

**********

Reviewer #1: Hello

This is a good article

The topic of the article is also interesting and new.

The topic of neuropathy in children and kidney diseases is very important and can have a great impact on the prevention and treatment of the disease.

Good luck.

Reviewer #2: Comments and reviewing points for the Author/Editor

1- The text of the introduction and the title are weakly consistent.

2- The type of study was not chosen well.

4- The study method has many shortcomings and is not acceptable.

5- The sample size was determined incorrectly and is too small.

6- Due to the small sample size, both most of the statistical calculations performed and the results presented are incorrect.

7- The discussion section is very poorly written.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Editor Comments:

Formatting and Style: We have revised the manuscript to comply with PLOS ONE’s style requirements, including the title page, figure formatting, and file naming conventions.

Data Availability Statement: All relevant data are available upon request from the corresponding author.

Reviewer #1:

General Comment: Reviewer #1 provided positive feedback on the novelty and relevance of the topic. We greatly appreciate their encouraging comments and have made no further changes in response to their feedback.

Reviewer #2:

Introduction and Title: We revised the introduction to better align with the clinical context and study objectives. The title has been updated to better reflect the scope of the study:

“Prevalence of uremic neuropathy and the effect of dialysis in children with end-stage renal disease: a cohort study.”

Study Design: We clarified our choice of a prospective cohort study and explained how it was designed to assess the prevalence and progression of uremic neuropathy in children with ESRD.

Methodology: We added a sampling section to better define inclusion criteria and clarified the nerve conduction study protocol and diagnostic methods.

Sample Size: We included a more detailed explanation of the sample size calculation, noting the practical constraints in recruiting pediatric ESRD patients and the rare nature of the disease.

Statistical Analysis: We described the statistical methods used for small sample sizes, clarified the tests applied, and acknowledged the limitations due to the sample size.

Discussion: The Discussion section has been rewritten to improve clarity and structure, including a summary of key findings, comparison with literature, and discussion of clinical implications and limitations.

Attachments
Attachment
Submitted filename: reviewers response .docx
Decision Letter - Ken Iseri, Editor

Dear Dr. Yahyaoui,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:  Apologies for the time taken to review. Some minor adjustments are required, please find  the reviewer's comment.

==============================

Please submit your revised manuscript by Nov 28 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Ken Iseri

Academic Editor

PLOS ONE

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #3: Yes

**********

Reviewer #3: The aim of the study was to determine the prevalence of UN in children with ESRD in a North

African cohort. The second objective was to assess the effect of dialysis on UN and associated

risk factors over a six-month period. Below please find my comments:

1. Authors indicate that the study aimed to assess UN in children ESRD in a North African population. The study was conducted in Tunisia, as far as I understand. Therefore, it would be better if the reference to North African population is removed everywhere and replaced by Tunisia as one of the North African countries.

2. Line 80 – please change to “Study Design”

3. In the Study Design section, please indicate where the study was conducted.

4. Line 85 – please define the Stage 5 chronic kidney disease, what are the criteria?

5. Line 107-110 – please define what T1 and T2 means.

6. In the ethics section, it is indicated that a consent was received from the patient or the legal guardian. The best practice is that the assent is received from the minor who is old enough. Since you had up to 18 year-olds, did you get assent (minor’s consent) or had only consent from the parent/legal guardian.

7. Line 180 – “-0.84 SD (±1.2; range: -2.7 to 2.4)” – I think it should be changed to -0.84 (SD ±1.2; range: -2.7 to 2.4). The same refers to other two SDs in the following sentences.

8. for the weight-for-age, height-for-age, BMI-for-age, indicate normal values.

9. Please define the abbreviation "PTH"

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org

Revision 2

Journal requirement:

The reference list was reviewed and updated to ensure accuracy and currency; no cited articles have been retracted.

Reviewer3: Comment 1: Authors indicate that the study aimed to assess UN in children ESRD in a North African population. The study was conducted in Tunisia, as far as I understand. Therefore, it would be better if the reference to North African population is removed everywhere and replaced by Tunisia as one of the North African countries.

Response: We thank the reviewer for this helpful clarification. We have replaced all mentions of “North African population” with “Tunisian population” throughout the manuscript.

Comment 2: Line 80 – please change to “Study Design.”

Response: Corrected as suggested.

Comment 3: In the Study Design section, please indicate where the study was conducted.

Response: We have added the location: “followed in Department of Pediatric Nephrology at University Hospital of Sahloul (Tunisia).”

Comment 4: Line 85 – please define Stage 5 chronic kidney disease, what are the criteria?

Response: We had already defined Stage 5 CKD in the Introduction (line 63-64) as “an eGFR < 15 mL/min/1.73 m² according to KDIGO 2024 criteria.” To improve clarity, we have now also repeated this definition briefly in the Study Design section (line 85) and updated the terminology to align with the KDIGO classification system (CKD G5, CKD G3..).

Comment 5: Lines 107–110 – please define what T1 and T2 mean.

Response: We added the clarification: “T1 refers to baseline assessment; T2 refers to the 6-month follow-up evaluation.”

Comment 6: In the ethics section, indicate whether assent from minors was obtained.

Response: Children were free to participate, decline, or withdraw from the EMG study at any time. We respected the child’s wishes, and any examination was immediately stopped if the child showed signs of discomfort or refusal. The EMG protocol was limited to a few nerves, and stimulation intensity was kept below 25 mA for motor nerves and 15 mA for sensory nerves to avoid activation of nociceptive fibers.

Comment 7: Line 180 – please adjust SD formatting.

Response: We corrected all SD expressions as suggested (now “-0.84 (SD ±1.2; range: -2.7 to 2.4)”).

Comment 8: For weight-for-age, height-for-age, BMI-for-age, indicate normal values.

Response: We have added reference ranges according to WHO growth standards (2007).

Comment 9: Please define the abbreviation “PTH.”

Response: Defined as “parathyroid hormone (PTH)” at first mention.

Attachments
Attachment
Submitted filename: Response to Reviewers 2.pdf
Decision Letter - Ken Iseri, Editor

<p>Prevalence of uremic neuropathy and the effect of dialysis in children with end-stage renal disease: a cohort study

PONE-D-25-17216R2

Dear Dr. Yahyaoui,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ken Iseri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #3: Yes

**********

Reviewer #3: (No Response)

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Ken Iseri, Editor

PONE-D-25-17216R2

PLOS ONE

Dear Dr. Yahyaoui,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ken Iseri

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .